The consequences of extended newborn screening programmes: Do we know who needs treatment?
- 22 February 2008
- journal article
- review article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 31 (2), 173-177
- https://doi.org/10.1007/s10545-008-0843-8
Abstract
The development of an evidence base for newborn screening is especially difficult because of the rarity of disorders now detectable. One consequence of expanded newborn screening is that physicians are being called upon to manage asymptomatic babies with persistent biochemical disturbances that indicate likely enzyme deficiencies. Some of these may be very mild. There is not always agreement as to who should be treated. Particular problems are seen with disorders that were previously thought very rare but are now found frequently by newborn screening. Some of these disorders appear benign or nearly so, and in the present state of knowledge should clearly not be included in routine newborn screening panels.Keywords
This publication has 29 references indexed in Scilit:
- A Delphi-based consensus clinical practice protocol for the diagnosis and management of 3-methylcrotonyl CoA carboxylase deficiencyMolecular Genetics and Metabolism, 2008
- Introducing new screens: Why are we all doing different things?Journal of Inherited Metabolic Disease, 2007
- 3-Methylcrotonyl-CoA Carboxylase Deficiency: Metabolic Decompensation in a Noncompliant Child Detected Through Newborn ScreeningPublished by American Academy of Pediatrics (AAP) ,2006
- Executive SummaryGenetics in Medicine, 2006
- Isolated 3‐methylcrotonyl‐coenzyme A carboxylase deficiency in a child with metabolic strokeJournal of Inherited Metabolic Disease, 2006
- Medium-chain acyl-CoA dehydrogenase deficiency: Genotype–biochemical phenotype correlationsMolecular Genetics and Metabolism, 2006
- Consanguineous 3‐methylcrotonyl‐CoA carboxylase deficiency: Early‐onset necrotizing encephalopathy with lethal outcomeJournal of Inherited Metabolic Disease, 2005
- Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Mutations Identified by MS/MS-Based Prospective Screening of Newborns Differ from Those Observed in Patients with Clinical Symptoms: Identification and Characterization of a New, Prevalent Mutation That Results in Mild MCAD Deficiency*American Journal of Human Genetics, 2001
- Familial hypotonia of childhood caused by isolated 3-methylcrotonyl-coenzyme A carboxylase deficiencyThe Journal of Pediatrics, 1992
- Isolated biotin‐resistant 3‐methylcrotonyl CoA carboxylase deficiency presenting with life‐threatening hypoglycaemiaJournal of Inherited Metabolic Disease, 1984